We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Dmh3.0
DMHA (Octodrine) Research
Mostly mechanism / observational
5 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most DMHA (Octodrine) studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from mixed-quality studies published 1967–2021.
Based on 5 studies
Confidence
Low confidence
By outcome
Safety, regulation & detection
Mostly mechanism / observational5 studies
Cardiovascular & sympathomimetic risk
Mostly mechanism / observational4 studies
Metabolic / weight-loss claims
Mostly mechanism / observational3 studies
Steady research
1 study in the last 5 years
196719942021
1Observational2021
In plain English: These cocktails of stimulants have never been tested in humans and their safety is unknown.
In plain English: Octodrine was found at a dose (±95% CI) of 72 ± 7.5 mg per serving ... The quantity of octodrine found in our study was more than twice the largest pharmaceutical dose.
Analytical study designed to find a new 1,3-DMAA-like stimulant in US supplements after the FDA banned DMAA — and it found octodrine (2-amino-6-methylheptane / DMHA)
Octodrine was present at ~72 mg per serving — more than twice the largest historical European pharmaceutical dose (8–33 mg)
Products also contained the analog 1,4-DMAA and the banned stimulants 1,3-DMAA and 1,3-DMBA, with 1,3-DMAA linked to hemorrhagic stroke and sudden death
In plain English: Octodrine is the trade name for Dimethylhexylamine (DMHA), a central nervous stimulant that increases the uptake of dopamine and noradrenaline ... Reported side-effects include hypertension, dyspnoea and hyperthermia.
Catalani V, Prilutskaya M, Al-Imam A, Marrinan S, Elgharably Y, Zloh M, et al. · Brain sciences (2018)
First pharmacology-focused review of octodrine/DMHA in seven decades — characterizes it as a CNS stimulant increasing dopamine and noradrenaline uptake, originally a 1950s nasal decongestant
Only five relevant scientific publications existed; most user information came from bodybuilding fora marketing it as 'the god of stimulants'
Reported harms include hypertension, dyspnoea, and hyperthermia, with concern about athlete safety and doping
In plain English: Fifteen Aconitum or Kigelia plant samples ... none of them contained 1,5-DMHA ... the enantiomeric distribution and the presence of the synthetic byproducts all suggested the synthetic origin of 1,5-DMHA in the commercial products.
Wang M, Haider S, Chittiboyina AG, Parcher JF, Khan IA · Journal of pharmaceutical and biomedical analysis (2018)
Counter-evidence to the marketing claim that DMHA is a 'natural' constituent of Aconitum or Kigelia plants — none of 15 plant samples contained it within the detection limit
DMHA in supplements was racemic and carried synthesis byproducts, indicating a synthetic, poor-quality source rather than a botanical extract
One product contained up to 112 mg per serving — over three times the highest European pharmaceutical dose